Mirna Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Mirna Therapeutics, Inc. - overview
Established
2007
Location
Austin, TX, US
Primary Industry
Pharmaceuticals
About
Founded in 2007 and based in Texas, US, Mirna Therapeutics, Inc. is a biopharmaceutical company that develops microRNA-based therapeutics for the treatment of liver cancer and hematological malignancies. In April 2015, Baxter Ventures led a USD 41. 8 million Series D financing for Mirna Therapeutics with participation from Eastern Capital, Santé Ventures, Morningside Ventures, Rock Springs Capital, and Celgene Corporation.
The company became public in 2015 raising USD 43. 8 million, and in May 2017, it merged with Synlogic, Inc.
Current Investors
Texas Emerging Technology Fund, Cancer Prevention & Research Institute of Texas, PTV Healthcare Capital
Primary Industry
Pharmaceuticals
Sub Industries
Biopolymers, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.mirnatherapeutics.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.